Evaluation of persistence of C. auris colonization
Objectives: Colonized patients are the main reservoir of Candidozyma auris and drive the increase in prevalence of this resistant pathogen.Solid data on duration of long-term persistence of C. auris colonization are limited, although often leading to prolonged contact precaution.Aim of this study was to evaluate the duration of C. auris colonization after discharge from an intensive care unit (ICU) endemic for C. auris.Methods: Single-centre, prospective study conducted in a hospital where endemic circulation of C. auris was observed in a single ICU.Monthly follow-up skin swabs were scheduled for patients once discharged to other non-endemic wards; after hospital discharge testing was performed during followup visits.Composite axilla and groin swabs were tested with PCR and conventional culture.Loss of colonization was defined by 2 consecutive negative swabs.Results: From January 2023 to December 2024, 50 C. auris-colonized patients were enrolled.Two or more control swabs were available for 37 patients (74%): 22/37 (59.4%) lost C. auris colonization after a median of 5 months (IQR 3-7, time to the second negative swab).At the last follow-up 14/37 patients (38%) were persistently colonized, and 6/14 developed candidemia.Higher Karnofsky Performance Status Score at the moment of enrolment and longer administration of antibiotics and antifungals (including for treatment of C. auris candidemia) were associated with persistence of colonization. Conclusions:When discharged to a non-endemic setting, almost 60% of patients lost C. auris colonization within 5 months after its first detection, suggesting a possible timeframe for reevaluation of colonization.
Authors
- F. Portunato
- M. Muccio
- A. Marchese
- A. Vena
- M. Bassetti
- L. Mezzogori
- E. Willison
- M. Mikulska
- M. Bavastro
- M. Bonaffini
- C. Bartalucci
- F. Centorrino
- V. Di Pilato
- L. Magnasco
- D.R. Giacobbe
Institutions
- Ospedale Policlinico San Martino (IT)
- University of Genoa (IT)
Publication Details
- Journal
- Clinical Microbiology and Infection
- Published
- 2026-05-01
- DOI
- https://doi.org/10.1016/j.cmi.2026.05.003
- Primary Topic
- Listeria monocytogenes in Food Safety
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Gilead Sciences
- Cidara Therapeutics
- Shionogi
- Tillotts Pharma
- Gilead UK and Ireland Corporate Contributions